XOMA (XOMA) Stock Forecast & Price Target

XOMA Royalty is a biotechnology royalty aggregator that has positioned itself as a key player in helping biotech companies advance their promising pre-commercial therapeutic candidates. With a diverse portfolio of over 120 assets, including 14 registrational/Phase 3 programs and 7 commercial assets, XOMA has a strong upside potential thanks to its creative deal-making abilities and non-dilutive cash flow. Investors should keep an eye on key assets such as Volixibat and Osavamator, and the company's promising acquisition by Ligand Pharmaceuticals. Furthermore, XOMA's unique royalty model and differentiated assets, including mezagitamab for IgA Nephropathy and a promising option for ITP patients, position the company for long-term success and the potential to generate significant royalties for its shareholders.

XOMA Royalty is a company that relies heavily on acquiring early to mid-stage clinical assets to drive its drug royalty aggregator business. However, recent news of a Phase 3 miss by partner company Rezolute raises concerns about the potential success of these assets. Additionally, while XOMA may have a strong cash position, its recent financial update showed lower than expected revenue, and it may struggle to continue acquiring deals in the future. With these various uncertainties, the outlook for XOMA Royalty's stock remains negative.